Live feed
·
INSIDERFilingvia Quantisnow
KalVista Pharmaceuticals Inc. logo

CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 6,875 shares and sold $67,669 worth of shares (4,347 units at $15.57), increasing direct ownership by 1% to 226,701 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KALV (KalVista Pharmaceuticals Inc.) and more on Quantisnow.